Physician profile
Rahul Singh
NPI 1528326329
$6,219.22
in general payments reported to CMS, 2019-2025
31 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $51.79 · 2021: $386 · 2022: $425 · 2023: $3,192 · 2024: $543 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553 · Honoraria: $1,500 · Travel and Lodging: $1,214 · Consulting Fee: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,552.70 |
| Honoraria | $1,500.00 |
| Travel and Lodging | $1,214.02 |
| Consulting Fee | $860.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $2,750.02 | 2023 | Monoferric |
| Incyte Corporation | $922.82 | 2019-2025 | Jakafi |
| Janssen Biotech, INC. | $586.32 | 2019-2025 | Darzalex, Rybrevant, Talvey |
| Novartis Pharmaceuticals Corporation | $208.52 | 2021-2023 | |
| Spr Therapeutics, INC | $171.67 | 2025 | Sprint Pns System |
| Abbott Laboratories | $147.56 | 2024 | Cardiomems |
| Beigene USA, INC. | $146.50 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $134.43 | 2020-2025 | Opdivo |
| Daiichi Sankyo INC. | $131.61 | 2024-2025 | Enhertu, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $129.65 | 2022-2023 | Alunbrig |
| Merck Sharp & Dohme LLC | $110.91 | 2019-2024 | Keytruda, Lynparza |
| Abbvie INC. | $94.19 | 2024-2025 | |
| Genentech USA, INC. | $92.94 | 2019-2025 | Venclexta, Tecentriq, Polivy |
| Mirati Therapeutics, INC. | $74.40 | 2023 | Krazati |
| Exelixis INC. | $69.87 | 2023-2025 | Cabometyx |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $54.26 | 2019-2023 | Lumakras |
| Gilead Sciences, INC. | $53.15 | 2023-2025 | Trodelvy |
| Foundation Medicine, INC. | $47.16 | 2019-2022 | |
| Celgene Corporation | $36.52 | 2019 | |
| Eagle Pharmaceuticals, INC. | $30.77 | 2024 | |
| Lilly USA, LLC | $27.73 | 2020 | |
| Coherus Oncology, INC. | $26.39 | 2021 | |
| Spectrum Pharmaceuticals INC. | $23.50 | 2025 | Rolvedon |
| Organon LLC | $22.89 | 2022 | |
| Glaxosmithkline, LLC. | $20.98 | 2025 | Jemperli |
| Octapharma USA, INC. | $20.40 | 2022 | |
| Aveo Pharmaceuticals, INC. | $19.67 | 2021 | |
| Eisai INC. | $17.03 | 2022 | |
| Menarini Silicon Biosystems, INC. | $16.82 | 2025 | |
| Myriad Genetic Laboratories, INC. | $16.40 | 2022 | |
| Pfizer INC. | $14.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.